| 2.15 -0.12 (-5.29%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.61 |
1-year : | 2.81 |
| Resists | First : | 2.24 |
Second : | 2.41 |
| Pivot price | 2.21 |
|||
| Supports | First : | 1.97 |
Second : | 1.63 |
| MAs | MA(5) : | 2.23 |
MA(20) : | 2.19  |
| MA(100) : | 2.25 |
MA(250) : | 4.34 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 55.8 |
D(3) : | 58.7 |
| RSI | RSI(14): 46.3 |
|||
| 52-week | High : | 12.51 | Low : | 1.63 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IOVA ] has closed above bottom band by 26.9%. Bollinger Bands are 67.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.25 - 2.27 | 2.27 - 2.28 |
| Low: | 2.07 - 2.08 | 2.08 - 2.09 |
| Close: | 2.12 - 2.15 | 2.15 - 2.17 |
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Fri, 17 Oct 2025
62,790 Options: Iovance Grants Inducement Awards to Nine New Hires at $2.24 Strike, 3-Year Vesting - Stock Titan
Fri, 17 Oct 2025
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Fri, 17 Oct 2025
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Unpacking a Potential 306% Upside in the Biotech Sector - DirectorsTalk Interviews
Wed, 08 Oct 2025
IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues - GlobeNewswire
Mon, 06 Oct 2025
Iovance Biotherapeutics (IOVA): Examining Valuation as Share Price Momentum Stalls - Yahoo Finance
Mon, 25 Aug 2025
Artisan Small Cap Fund Exited Its Stake in Iovance Biotherapeutics (IOVA) Due to Operational Challenges - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 362 (M) |
| Shares Float | 304 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 69.4 (%) |
| Shares Short | 72,970 (K) |
| Shares Short P.Month | 71,320 (K) |
| EPS | -1.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.03 |
| Profit Margin | -161.5 % |
| Operating Margin | -189.8 % |
| Return on Assets (ttm) | -27.5 % |
| Return on Equity (ttm) | -53.2 % |
| Qtrly Rev. Growth | 92.6 % |
| Gross Profit (p.s.) | 0.13 |
| Sales Per Share | 0.66 |
| EBITDA (p.s.) | -1.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -303 (M) |
| Levered Free Cash Flow | -144 (M) |
| PE Ratio | -1.78 |
| PEG Ratio | 0 |
| Price to Book value | 1.05 |
| Price to Sales | 3.22 |
| Price to Cash Flow | -2.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|